Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLBS

Caladrius Biosciences (CLBS) Stock Price, News & Analysis

Caladrius Biosciences logo

About Caladrius Biosciences Stock (NASDAQ:CLBS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.43
$8.38
52-Week Range
N/A
Volume
466,373 shs
Average Volume
522,308 shs
Market Capitalization
$26.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLBS Stock News Headlines

Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
CLBS Caladrius Biosciences, Inc.
See More Headlines

CLBS Stock Analysis - Frequently Asked Questions

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.95) by $0.15.

Caladrius Biosciences shares reverse split before market open on Thursday, September 15th 2022.The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caladrius Biosciences investors own include Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Alphabet (GOOG), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/04/2021
Today
9/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBS
CIK
320017
Employees
27
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.47 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-27.24%
Return on Assets
-26.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.33
Quick Ratio
22.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
60,583,000
Free Float
59,250,000
Market Cap
$26.05 million
Optionable
Optionable
Beta
0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CLBS) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners